CSIMarket
 
Wave Life Sciences Ltd   (WVE)
Other Ticker:  
 
 
Price: $4.4100 $0.32 7.824%
Day's High: $4.44 Week Perf: 12.79 %
Day's Low: $ 4.01 30 Day Perf: 0.23 %
Volume (M): 1,014 52 Wk High: $ 6.94
Volume (M$): $ 4,472 52 Wk Avg: $4.56
Open: $4.07 52 Wk Low: $3.15



 Market Capitalization (Millions $) 472
 Shares Outstanding (Millions) 107
 Employees -
 Revenues (TTM) (Millions $) 85
 Net Income (TTM) (Millions $) -85
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 2

Wave Life Sciences Ltd
Wave Life Sciences Ltd is a clinical-stage genetic medicine company that was founded in 2012 and is headquartered in Singapore. The company is dedicated to developing RNA-targeted therapies for the treatment of rare genetic diseases and has two primary product platforms e stereopure oligonucleotides and allele-selective therapeutic candidates.

The stereopure oligonucleotide platform focuses on the creation of oligonucleotide-based therapeutics that are designed to selectively target and modulate the expression of specific disease-causing genes. These therapeutics are engineered using proprietary synthetic chemistry and manufacturing processes that eliminate impurities and maximize potency and precision.

The allele-selective therapeutic platform is designed to develop targeted therapies that specifically address genetic mutations associated with hereditary disorders. These therapies are designed to selectively target the mutant form of a gene while leaving the healthy, wild-type gene intact.

Wave has a broad pipeline of investigational therapies across neurology, ophthalmology, dermatology, cardiology, and other therapeutic areas. The company has a number of clinical programs underway, including in Huntington's disease, DMD, and acute myeloid leukemia, as well as early-stage programs in other genetic diseases such as Duchenne muscular dystrophy, ALS, and Friedreich's ataxia.

In addition to its research and development efforts, Wave is also focused on building strategic partnerships with other leading biotech and pharmaceutical companies to co-develop and commercialize its therapies. The company has established partnerships with several key industry players, including Takeda, Pfizer, and Vertex Pharmaceuticals.

Overall, Wave Life Sciences Ltd is a pioneer in the field of RNA-targeted therapies, with a broad range of innovative therapeutics under development that have the potential to transform the lives of patients with rare genetic diseases. The company is well-positioned for future growth and success in this rapidly evolving field.


   Company Address: 7 Straits View #12-00 East Tower 18936
   Company Phone Number: 6236 3388   Stock Exchange / Ticker: NASDAQ WVE
   WVE is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Wave Life Sciences: Pioneering Breakthroughs in DMD Treatment and Experiencing Exponential Revenue Growth

Published Fri, Dec 15 2023 1:30 PM UTC

Wave Life Sciences Announces Promising Trial Initiation and Significant Revenue Growth
Wave Life Sciences Ltd, a leading biotechnology company, has recently announced the initiation of dosing in the Phase 2 FORWARD-53 Trial of WVE-N531 for the treatment of Duchenne Muscular Dystrophy (DMD). This significant milestone marks a step forward in the development of a potentia...

Financing Agreement

CAMBRIDGE, Mass, Dec 06, 2023 - In an exciting development, Wave Life Sciences Ltd (Nasdaq: WVE), a renowned clinical-stage RNA medicines company, has recently revealed its plans to embark on an underwritten public offering With a commitment to transforming the lives of individuals grappling with devastating diseases, Wave aims to raise $100 million in aggregate from the sale of its ordinary shares and pre-funded warrants, offering potential investors an opportunity to contribute to groundbreaking treatments

Published Wed, Dec 6 2023 9:10 PM UTC

CAMBRIDGE, Mass., Dec. 06, 2023 - In an exciting development, Wave Life Sciences Ltd. (Nasdaq: WVE), a renowned clinical-stage RNA medicines company, has recently revealed its plans to embark on an underwritten public offering. With a commitment to transforming the lives of individuals grappling with devastating diseases, Wave aims to raise $100 million in aggregate from the...

Clinical Study

Wave Life Sciences Announces Promising Results for Groundbreaking RNA Editing Therapy in Alpha-1 Antitrypsin Deficiency

Published Wed, Dec 6 2023 9:09 PM UTC



In a significant milestone for medical science, Wave Life Sciences Ltd has announced the initiation of dosing in the RestorAATion clinical program, which is evaluating the first-ever RNA editing candidate, WVE-006, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). AATD is a rare genetic disorder that can lead to serious lung and liver complications. This ...

Wave Life Sciences Ltd

Wave Life Sciences Reports Remarkable Revenue Growth and Positive EPS Amidst Industry Downturn

Wave Life Sciences Ltd, a major player in the pharmaceutical preparations industry, has seen a significant increase in revenue in its most recent fiscal period. Despite the challenges faced by many companies in the industry, Wave Life Sciences has managed to turn around its income and post a positive earnings per share (EPS) of $0.07.
In the third quarter of 2023, the company flourished while others struggled with diminishing orders and declining top-line. Compared to the previous quarter, Wave Life Sciences saw a substantial improvement in its financials. Net profit per share turned positive, rising from -$0.20 to $0.07, and revenue doubled by an impressive 122.627% from $22.11 million to $49.21 million.

Wave Life Sciences Ltd

Wave Life Sciences Ltd Shows Stellar Performance: Reports Significant Revenue Growth and Reduced Losses in Recent Fiscal Period

Wave Life Sciences Ltd, a leading biotechnology company, recently announced its financial results for the fiscal second quarter of 2023. The company showcased impressive performance, demonstrating significant improvements in several key financial metrics compared to the prior year.
In terms of earnings per share, Wave Life Sciences reported a loss of $0.20 per share for the fiscal second quarter of 2023. This was a significant improvement from the loss of $0.62 per share reported in the same period a year ago. Furthermore, earnings per share also improved from the preceding reporting season, where the company reported a loss of $0.27 per share. This indicates positive developments in the company's financial performance and a potential turnaround in profitability.
The revenue for Wave Life Sciences witnessed a remarkable surge during the fiscal second quarter of 2023. The company reported revenue of $22.11 million, which represents a staggering 5794.933% increase from $0.38 million in the corresponding reporting season a year prior. Moreover, on a sequential basis, the revenue surged by 70.98% from $12.93 million, reflecting the company's ability to generate substantial growth in a short span of time.






 

Wave Life Sciences Ltd's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com